AstraZeneca understands the impact that autoimmune disease has on people’s quality of life. That’s why we’re working on trials such as JASMINE, to hopefully find a new treatment that could improve the symptoms of polymyositis and dermatomyositis.
It is believed that an excess of certain immune system proteins (Type I interferons) play an important role in polymyositis and dermatomyositis. JASMINE is looking to see if a study therapy called SAPHNELO® may be effective in treating people with polymyositis and dermatomyositis.
SAPHNELO® is the brand name for the medication anifrolumab. Anifrolumab is a man-made antibody that blocks type I interferons and may reduce disease activity in patients with polymyositis or dermatomyositis. SAPHNELO® is already approved in the United States to treat adults with lupus but has not yet been approved by the FDA for treating adults with polymyositis or dermatomyositis, so its use in this trial is investigational.
How can I join JASMINE?
You May Also Like
JASMINE may be the right trial for you if you:
- Are getting treatment for polymyositis or dermatomyositis but still have symptoms
- Are between 18 and 75 years old
Additional criteria may apply.